Bruce Dias 
Cancer research is no longer focused solely on discovering how we can kill cancer cells. This is because scientists have found out how important the metabolic system is in the development of this condition, and how cancer cells often rewire their energy and those metabolic systems in order to survive under stress, to grow rapidly, as well as to resist therapy. Research has, therefore, shifted towards understanding those particular processes, as well as towards finding ways to stop them.
And, of course, there are various processes and pathways that therapies should target, and that researchers want to know more about. Targeting the mitochondrial oxidative phosphorylation (OXPHOS) is one of the emerging approaches in cancer research, therefore. And, OXPHOS is actually the process through which mitochondria produces the bulk of that cellular ATP, that is, energy, so it is no wonder that it is a process that has been the subject of many researches.
Now, the idea is, naturally, for scientists to develop drugs that could target that specific process and pathway. And, well, IACS-010759 (IACS-10759) OXPHOS inhibitor has come up as a potential solution. That is, as a drug that could potentially block that process and thus help in developing a better treatment course for cancer patients. Targeted therapies have long been studied, and this particular drug helps with one of them, targeting OXPHOS specifically.
Chances are that, regardless of whether you are a researcher or you simply have a curious mind, you have come across this particular drug already, and you’ve become interested in understanding it better. All of that means that you have quite some questions on your mind, and what we are going to do right now is answer them for you below. Understanding IACS-010759 (IACS-10759) OXPHOS inhibitor better is sure to help your researching processes and studies, if you have any underway, as well as to generally soothe your curiosity. So, let’s start sharing the info you need here.
What Is OXPHOS & Why Inhibiting It Matters?
Whenever learning about something new, we have to start with the basics. And, things are no different here. Only, this time, the basics have to cover something else, and not the drug itself, because you cannot understand the actual drug if you don’t really understand the process that it is used for in the first place. What I am trying to say here is that understanding OXPHOS is essential, so let us find out what it is and why inhibiting it is so important.
As I have mentioned already, OXPHOS is actually a process through which the bulk of cellular energy is produced, via the electron transport chain. This increases the cellular capacity to grow, divide and literally stay alive. And, while that seems like a completely normal process, which it is when we are talking about healthy cells, it can actually cause quite some issues when it comes to cancer cells.
After all, what scientists are trying to do is stop those tumors from growing, dividing, attaching to surrounding tissues, and similar things, and if the above process is overactive, that can be impossible. This is why targeting OXPHOS, and looking for a way to inhibit it, is important, as it can help make cancer cells more vulnerable, and thus more responsive to treatment. All of that is sure to eventually lead to their death, which is what scientists are trying to achieve through various cancer treatments.
What Is IACS-010759 (IACS-10759) OXPHOS inhibitor?
Okay, let us now start talking about the drug itself. So, in short, IACS-010759 (IACS-10759) OXPHOS inhibitor is a small molecule drug that is aimed at inhibiting the process we have talked about above. More precisely, it is designed to inhibit the mitochondrial complex I, which is basically the first enzyme in the actual mitochondrial electron transportation chain. Doing this leads to reducing mitochondrial respiration, and, therefore, diminishing the cells’ capacity for OXPHOS. I suppose you understand how this can make tumors more vulnerable and more responsive to treatment, which is the end goal here.
Another thing you should know about IACS-010759 (IACS-10759) OXPHOS inhibitor is that it is actually formulated to be taken orally. That, in essence, makes it more convenient and easier to dose, allowing patients to take pills, instead of having to be administered injections and infusions in hospitals. No doubt that this is also a huge plus that makes the entire treatment process easier for a lot of patients.
Read more about the inhibitor itself here: https://pubmed.ncbi.nlm.nih.gov/29892070/
In addition to that, you should be aware of the fact that this drug is considered to be quite potent. And, of course, the fact that it is selective, targeting the mitochondrial complex I specifically, is another advantage you should know. This specific advantage means that patients can expect fewer side-effects, which is basically the idea behind all targeted therapies.
While this drug shows quite some promise, we cannot fail to mention that it is still undergoing important research. So, we can expect some new findings in the future. For now, it is used only in research, and it is still not an approved standalone drug. But, who knows what the future holds.
What to Expect From Research in the Future?
What is it, though, that we can expect from those future research processes? There are some indications about it. And, while I am now going to share nothing but assumptions, you should keep in mind that those assumptions are based on what it is that is known so far, so they are definitely grounded in reality.
For one thing, we can expect evidence about IACS-010759 (IACS-10759) OXPHOS inhibitor being highly effective when paired with some other treatment processes, such as chemotherapy, immunotherapy, targeted therapy and similar. Then, the scientists are using molecular profiling to actually identify the tumors that depend on this mitochondrial process, which can lead to the development of better treatment therapies for those. Of course, they are also looking for ways to reduce toxicity and thus allow for a much safer therapeutic window, which will result in fewer side-effects during treatment.
